Abstract: Treatment of hypereosinophilic syndrome with dupriulizumab has been reported abroad, but not in China. Herein, we report a case of dupriulizumab in the treatment of hypereosinophilic syndrome successfully. The patient received subcutaneous injection of dupilumab at an initial dose of 600 mg, 300 mg after 1 week, then once every 2 weeks with a dose of 300 mg. After 3 weeks of treatment, the pruritus was significantly relieved, and the skin lesions basically subsided after 7 weeks. Erysipelas appeared on the 3rd day after the first dose of treatment, which was improved by anti-infection.

Key words: hypereosinophilic syndrome, dupilumab, erysipelas